Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation

Omid Tavassoly(Montreal Neurological Institute and Hospital), Edward A. Fon(Montreal Neurological Institute and Hospital)
Neurotherapeutics
March 12, 2021
Cited by 26


Related Papers